Accord Healthcare Strengthens Specialty Business Offering with Exciting New Hire
Chrys Kokino, a global leader in speciality pharmaceuticals joins Accord as President, US Specialty
Accord Healthcare further strengthens their specialty business offer with the addition of Mr. Chrys Kokino as President, US Speciality. While retaining its position as one of the leading suppliers of generic medicines, Accord have also been steadily growing their speciality products business that combines innovative design, technology or approaches with complex and value-added medicines to provide significant advantages to patients and / or healthcare professionals.
Binish Chudgar, Vice Chairman and Managing Director of Intas (the parent company of Accord Healthcare) said, “We are excited to have someone of Chrys’ experience join our team. His expertise will help us continue to realise the value of our rapidly growing specialty products business.”
Chrys has more than 30 years’ experience in leading multiple teams within specialty pharmaceutical organisations such as Bristol Myers Squibb, Amgen, and Hoffman – La Roche. Chrys then joined Sandoz and marketed and commercialized the first global biosimilars. Most recently, he was the Global Head of Biologics & Insulins – Commercial, as Mylan commercialized seven biosimilars in the worldwide markets.